default_side_ad1

default_nd_ad2

Most viewed

• 1Bio‘Invossa, first treatment to have used cancerous cell lines’
• 2OpinionReporter’s Notebook[Reporter’s Notebook] Concerns over TB risk rise amid more use of TNF-α inhibitors
• 3SpecialSpecial Series in Celebration of KBR’s 2nd AnniversaryPharma in Battle[Special] Interleukin inhibitors Cosentyx, Taltz target psoriasis market
• 4BioCelltrion completes patient registration for Humira biosimilar
• 5SpecialInterview with global pharma[Interview with global pharmas] ‘GSK Korea goes all out to help Korean patients, host nation's healthcare system’
• 6BioAlteogen wins patent on SC injection formulation for Herceptin biosimilar
• 7BioCelltrion licenses out hypertrophic cardiomyopathy treatment to Japan

set_C1

default_side_ad2

default_side_ad3

default_side_ad4

default_nd_ad6